[A15-13] Ruxolitinib – Benefit assessment according to §35a Social Code Book V (dossier assessment)
Last updated 15.07.2015
Project no.:
A15-13
Commission:
Commission awarded on 08.04.2015 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A15-35 | Ruxolitinib (Addendum to Commission A15-13) | Commission completed |
| A14-17 | Ruxolitinib – Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| G12-03 | Ruxolitinib - Assessment according to § 35a (para. 1., sentence 10) Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2015-10-15 A G-BA decision was published.